Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2008

Biodel Plans Manufacturing Facility for Injectable Insulin Product

  • Biodel reported plans to build and operate a fill and finish manufacturing facility for its Phase III injectable insulin product, VIAject™.

    Biodel anticipates that the site will cost under $15 million. The plant, to be located on the campus of Biodel’s headquarters in Danbury, CT, will be available for commercial production in 2009, according to the company.

    The firm  expects that the dedicated production plant will improve margins, provide superior quality control, and better inventory control.

    VIAject is Biodel’s lead candidate. It is being developed as a rapid-acting form of injectable human insulin for meal-time use by patients with type 1 or type 2 diabetes.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »